Company ProfilePremium

SomnoMed Limited

Company Profile Analysis

Ticker: SOM.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
SomnoMed Limited - Company showcase

Year Founded & Workforce

2004

400 Employees

SomnoMed Limited logo

SomnoMed Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

SomnoMed Limited Overview

SomnoMed is the self-described global market leader in custom oral appliance therapy (OAT) for obstructive sleep apnea (OSA), snoring and sleep bruxism. It designs, manufactures and sells prescription mandibular advancement devices under the SomnoDent family and related brands (Flex, Fusion, Classic, Avant, Herbst Advance Elite, and the new Virtus). Dentists fit the devices on referral from sleep physicians, in a reimbursed medical-device channel. The company has treated more than one million patients, which it says is a first for any OAT company. About 95% of revenue is earned outside Australia: Europe accounts for about 54%, North America about 40%, and APAC the remainder. After a 2023–24 manufacturing crisis and two dilutive recapitalisations, SomnoMed rebuilt capacity, returned to positive EBITDA (A$10.9m in FY26) and eliminated its debt. Its differentiating technology bet is Rest Assure, the first oral appliance with FDA-cleared in-built compliance monitoring. Its near-term challenge is restoring growth after a weak second half of FY26 in Europe, a CEO consolidation and a share price down about 55–60% in 2026.


Company's own description

SomnoMed describes itself in ASX releases as "a public company providing treatment solutions for sleep-related breathing disorders including obstructive sleep apnea, snoring and bruxism." In its FY26 investor presentation (August 2026) it states its vision as "a world where our oral appliance therapy is the standard of care for obstructive sleep apnea treatment." Its mission statement positions it as "the global leader in oral appliance therapy" that sets the standard for outcomes, innovation and patient experience. The Annual Report 2025 describes the group as producing and selling devices for the oral treatment of sleep-related disorders in Asia Pacific, North America and Europe.

Independent characterisation

SomnoMed is a vertically integrated, mid-sized dental medical-device manufacturer. Its products are custom, patient-specific Class II (US) medical devices. Each device is made to order from a dentist's impression or intra-oral scan, produced in SomnoMed's own manufacturing facilities using CAD/CAM, milling and finishing, and shipped back to the dentist for fitting.

The economic engine is a per-device unit sale. The FY26 MAS device gross margin was 71.5%, and group gross margin was 61.1% after lower-margin ancillary and distributed items. Demand is driven by a referral chain: patient → physician or sleep test → diagnosis → prescription → dentist → SomnoMed lab. Reimbursement by Medicare, private insurers and European statutory insurers strongly shapes volume.

Business model and revenue mix

Revenue streamDescriptionDisclosure
Custom oral appliances (MAS)SomnoDent family, HAE, Virtus; sold per unit to dentists, clinics and distributorsThe large majority of revenue; exact % not separately disclosed
Ancillary productsCleaning tablets (SOMTabs, proprietary), accessories, replacement and refurbishment—
Health Care Company (HIC) revenue – NetherlandsRevenue associated with Dutch "Health Care Companies" channel arrangementsSeparately called out in FY23 Europe commentary ("excluding HIC")
Connected care / software (future)Rest Assure compliance-monitoring device plus app/docking station; potential recurring data or service revenuePre-commercial; commercialisation expected FY27 (1H FY26 commentary)
Subscription / licensingNone material disclosed—

Mix assessment: Effectively about 100% product revenue today. There is no material service, subscription or licensing income. Rest Assure is the only route to a technology-enabled or recurring component.

Value-chain position

SomnoMed sits at the device design and manufacturing node and controls distribution through direct sales forces in key markets. It does not diagnose OSA; that is done by sleep labs, physicians and home sleep tests. It also does not fit devices; that is done by dentists. Its customers are dentists (it cites a potential customer pool of 700,000+ dentists in key regions). The end-users are patients, and the payers are insurers and governments. Upstream inputs are dental polymers and metals, milling equipment and 3D printing consumables.

Customer types and end-markets

Customer / end-marketRole
General and sleep-specialised dentistsDirect purchasers; fit and titrate devices
Sleep physicians, ENTs, GPsReferral sources (prescribers)
Health insurers and statutory payers (e.g., US Medicare via CMS codes; European statutory insurers)Reimbursement gatekeepers
Patients (self-pay in non-reimbursed markets such as parts of APAC)End-users; price-sensitive when out-of-pocket
Dutch Health Care Companies (HIC)Channel partners in the Netherlands
Pharma (GLP-1 manufacturers)Emerging collaborators. The company reports "continued engagement with GLP-1 manufacturer" (FY26 presentation).

Strategy

Stated strategy themes (FY26 Results Presentation, August 2026)

Management frames FY24–FY26 as "Financial & Operational Turnaround". In that phase it cleared debt, generated positive cash flow, invested in talent and increased capacity to improve turnaround times. It frames FY27–FY30 as "Growth & Profitability Objectives":

  1. Return to double-digit revenue growth.

  2. Progressively expand EBITDA margins through scale and efficiency gains.

  3. Organic growth focus, with consideration of small-scale acquisition opportunities.

The three-pillar growth plan ("A Bold Vision to Drive Growth FY27 & Beyond"):

  1. Capture the growing patient pool. Targets GLP-1 and other pharma-led diagnosis trends, connected care and home diagnostics, and CPAP failures (up to 50% of CPAP patients discontinue).

  2. Accelerate new products aligned to market needs. Virtus now; Connected Care / Rest Assure next.

  3. Expand referring and treating clinicians. Clinician connectivity and engagement, and an expanded reimbursement framework.

A detailed strategic roadmap is to be presented at the 23 November 2026 AGM.

Initiatives announced in the last 24 months

InitiativeDateDetailStatus
Manufacturing capacity expansionFY25–FY26Capacity +50% (FY25), +20% (FY26); production times down more than 50%; further site expansion plannedOngoing; capex A$5.7m in FY26
Rest Assure clinical and regulatory programFY25–FY27FDA 510(k) for compliance cleared October 2024; pre-submission and US clinical study protocol to support a treated-AHI efficacy 510(k) (AGM November 2025)Commercialisation expected FY27 (1H FY26 commentary)
Virtus launchJuly 2026Global controlled market release for OSA plus bruxismBroad adoption assumed from 2H FY27
Leadership build-outFebruary 2026New Chief Marketing Officer and Chief Transformation Officer rolesCTO promoted to COO, July 2026
CEO consolidation27 July 2026Move from co-CEO to sole CEO (Karen Borg)Complete
Board renewal16 October 2026Russo retires; Price becomes ChairEffective at AGM, 23 November 2026
Europe recovery planJuly–August 2026Targeted actions after reimbursement and referral changes; dedicated product strategies; reimbursement improvement application in a key marketIn progress
North America CMS strategyFY26–FY27Product innovation aimed at the most accessible CMS (Medicare) codes; cohort-specific demand generationIn progress
GLP-1 engagementFY26"Continued engagement with GLP-1 manufacturer"Nature of relationship not disclosed
APAC resetFY26–FY27Restructured leadership; product line extensions for non-reimbursed markets under investigationIn progress
Free-float improvementSeptember 2025A$11.25m block trade (16.07m shares at A$0.70) to diversify the registerComplete
Cost restructuring ("tranche 3")FY26One-off cost of A$0.7mComplete

Guidance and medium-term targets

PeriodGuidanceOutcome
FY24 (initial)Revenue growth ≥12%; capex A$5mCut April 2024 to 6–9% growth and EBITDA of –A$1m to A$0m; actual +9.6%, EBITDA A$0.6m
FY25 (initial, August 2024)Revenue about A$100m; EBITDA >A$5m; capex A$3–4mRaised to about A$105m in February 2025; actual A$111.5m and EBITDA A$9.2m (beat)
FY26 (August 2025)Revenue A$119–126m; EBITDA A$10–12m; capex A$6–8mRevenue A$114.5m (miss); EBITDA A$10.9m (in range); capex A$5.7m (below)
FY27 (July / August 2026)High-single-digit revenue growth; EBITDA margin consistent with FY26 (about 9.6%). The formal range is to be issued at the AGM on 23 November 2026.Pending
FY27–FY30Return to double-digit growth; progressive EBITDA margin expansionAspirational; no numeric target

Key FY27 assumptions stated: continued North America growth and EU stabilisation, global Virtus adoption in 2H FY27, stable margins while investing, and FX.

ESG and sustainability commitments: None quantified in the retrieved materials.

Products & Services

All devices are custom-made, prescription mandibular advancement splints or devices (MAS/MAD). They hold the airway open by positioning the lower jaw forward, which the company calls Continuous Open Airway Therapy (COAT). Pricing to dentists is not publicly disclosed for any product.

FY26 strategic portfolio framing (FY26 presentation, "A Bold Vision to Drive Growth FY27 & Beyond"):

Existing: HAE, Classic, Flex, Fusion

New: Virtus

Future: Connected Care / Rest Assure

  • Product line extensions for non-reimbursed environments are under investigation.

Product Portfolio

ProductSegment focusDescription and key capabilitiesTarget patientLaunch / statusNotes

SomnoDent Classic

Global

The original twin-block style SomnoDent MAS; adjustable advancement

Mild-to-moderate OSA, snoring

Original platform (2004 lineage)

Listed among "existing" products in the FY26 roadmap

SomnoDent Flex

NAM-led, global

Twin-block MAS with flexible/soft-lined design for comfort; built to satisfy US reimbursement criteria

OSA patients in reimbursed US channel

Established

FY26 presentation: "Designed for US Reimbursement / Medicare Reimbursed"

SomnoDent Fusion

NAM-led, global

Hybrid hard/soft construction MAS; Medicare-reimbursable design

OSA, Medicare beneficiaries

Established

Grouped with Flex in the FY26 portfolio slide

SomnoDent Avant

NAM, Europe

Low-profile, minimal-bulk design aimed at comfort and adherence

Comfort-sensitive OSA patients

Launched mid/late 2010s

Did not obtain full US Medicare reimbursement in FY23; appeal pursued (Annual Report 2023)

Herbst Advance Elite (HAE)

Europe

Herbst-mechanism (telescopic arm) MAS reimbursed across key European markets

OSA patients in European statutory systems

Established

FY26 presentation: "Established European Platforms / Reimbursed across Key European Markets"

Virtus

Global

Next-generation oral appliance designed for patients with OSA plus coexisting sleep bruxism (teeth grinding/clenching), a cohort the company estimates at about 50% of OSA patients (citing Li et al., J Clin Sleep Med 2023, 914 adults)

OSA patients with bruxism

Global controlled market release commenced July 2026; broad adoption assumed from 2H FY27

Management: strengthens position in an "underserved segment"

Rest Assure

NAM first, then EU and APAC

First OAT with in-built sensor for objective, all-night compliance monitoring; docking station plus patient app; designed to enable large-scale real-world data and, potentially, direct-to-patient marketing

Patients and prescribers wanting objective adherence data (parity with CPAP data)

FDA 510(k) K233497 cleared 3 October 2024 (compliance monitoring only); efficacy (treated-AHI) claim to require a further 510(k) supported by a US clinical study; commercialisation expected FY27

The company positions it as a premium product; "Connected Care / Rest Assure" is listed as "Future" in the FY26 roadmap

SomnoDent with micro-recording

NAM

Earlier-generation SomnoDent with embedded third-party compliance micro-recorder

Prescribers needing compliance data

FDA 510(k) cleared in the mid-2010s

Precursor to the fully integrated Rest Assure

SOMTabs

Global

Proprietary appliance cleaning tablets

All SomnoDent users

Established

Supply and manufacturing issues noted in Annual Report 2023

Sleep bruxism / snoring appliances

Global

Oral devices for bruxism and simple snoring

Non-OSA patients

Established

The company lists bruxism and snoring within its treatment scope

Digital workflow (intra-oral scan intake, CAD/CAM)

Global

Fully digital SomnoDent manufacturing ("two fully digitally made SomnoDent" products, Annual Report 2022)

Dentists using intra-oral scanners

2022 onward

Enabler of capacity expansion (+40% over FY25–FY26)

Financial Narrative

Income statement

Sources: FY22 revenue and EBITDA: FY22 results and Annual Report 2022. FY23: Annual Report 2023 (EBITDA A$2.1m; device GM 72%). FY24: FY26 presentation ("vs A$0.6m FY24") and Quartr (FY24 revenue A$91.7m, +9.6%). FY25–FY26: FY26 Results Presentation and Appendix 4E. FY23–FY25 NPAT and EPS: InvestSMART/Morningstar financial summary.

FY26 EPS is approximate (Investing.com TTM –A$0.012). Simply Wall St reports FY24 EPS as –A$0.10, versus –7.6c from InvestSMART. The discrepancy likely reflects weighted shares around the April–May 2024 rights issue. FY23 EBITDA is A$2.1m on the company definition, while InvestSMART shows A$0.7m on a different basis; the company figure is used.

Operating income (EBIT) is not reported as a statutory line in the retrieved materials. Craft reports 1H FY26 EBIT of A$2.8m.

Revenue CAGR FY22–FY26: (114.5 / 72.6)^(1/4) – 1 = 12.1% per year. The FY21–FY26 five-year CAGR, based on FY21 revenue of A$62.7m, is 12.8%.

Commentary. The five-year revenue line shows steady double-digit growth, except in FY24, when the manufacturing crisis capped shipments, and FY26, when Europe and FX weighed. The transformation is in profitability. EBITDA moved from roughly breakeven (FY22–FY24) to A$9–11m (FY25–FY26), driven by three factors:

  • Operating leverage on more than A$20m of incremental revenue in FY25.

  • Cost restructuring across three tranches of programs.

  • A recovery in gross margin to 61.1% as manufacturing yields improved.

Statutory losses persist for three reasons:

  • Share-based payments of A$3.6m in FY26, which are non-cash and higher year on year.

  • Unrealised FX of A$1.1m.

  • Tax of A$2.2m paid on profitable European and US subsidiaries, while Australian and corporate losses are not tax-effected.

FY26's 2H revenue decline (–7% reported, –1% constant currency) is the key inflection investors are now weighing.

Half-year profile

2H FY26 figures are derived as FY26 minus 1H FY26 and should be treated as derived, not reported. Sources: 1H FY24/1H FY25/1H FY26 half-year releases.

The seasonality is structural. 1H (July–December) benefits from patients claiming before calendar-year insurance resets, particularly in Europe and the US (company commentary, FY25 and FY26).

Balance sheet

Sources: FY25–FY26 from FY26 Results Presentation; FY22 cash from Annual Report 2022; FY24 cash from 1H FY25 release; equity and long-term debt FY23–FY25 from InvestSMART/Morningstar. At 31 December 2025, total assets were A$79.9m and equity A$50.0m (1H FY26 report).

Short/long debt split. The residual A$0.4m (FY26) is "European government-backed borrowings" (FY26 presentation). A short/long-term split was not disclosed in the summary.

Working capital (derived from listed items). Receivables plus inventory minus payables equals A$6.4m in FY25 and A$5.5m in FY26. The improvement came from better collections and lower prepayments and accruals.

Commentary. The balance sheet was rebuilt by two raises: A$15.5m gross in September 2023 at A$0.60 and A$22.6m gross in April–May 2024 at A$0.21. These lifted equity from A$24.5m (FY23) to A$45.9m (FY24) and allowed repayment of the drawn A$16m facility. Since FY24, the business has self-funded, and cash has held at about A$17m despite capex rising to A$5.7m. Intangibles (A$22.4m) consist mainly of capitalised development (Rest Assure, digital manufacturing) and legacy goodwill.

Cash flow

Notes: The FY23 raise was completed in September 2023, which falls in FY24 by settlement date. It is placed here at announcement (31 August 2023, the FY23 results day) and is in substance an FY24 inflow, alongside the A$22.6m April 2024 raise. In FY26, financing inflow included A$2.0m from the employee share trust repaying its loan on 2.86m shares sold in the September 2025 block trade. 1H FY24 operating cash flow was –A$4.6m. Source: FY26 Results Presentation cash flow summary.

Commentary. Cash conversion is good at the EBITDA line: operating cash flow before leases was 76% of EBITDA in FY26. Tax paid (A$1.4m) and one-off settlements (A$0.9m) consume part of it. Capex is the swing factor: FY26 guidance was A$6–8m, and A$5.7m was delivered. More than 50% of capex went to growth and manufacturing capacity, which pushed FCF slightly negative. Management's framing is that the business can fund capacity and R&D internally but has little surplus for large M&A.

Key ratios

Sources and derivations: ROE FY23–FY25 from InvestSMART/Morningstar. FY26 ROE is derived as –2.65 / 47.4. ROA, asset turnover, net debt/EBITDA and D/E are derived from disclosed FY25–FY26 balance-sheet and P&L items. FY26 interest was nil, so coverage is not meaningful. Including lease liabilities, gross debt to equity was 0.17x (FY25) and 0.11x (FY26).

The listed current items alone (cash, receivables and inventory of A$39.1m against payables and current tax of A$17.4m) imply comfortable liquidity of more than 2x.

ROIC: Negative on a statutory basis. On an underlying basis, EBITDA less D&A and leases gives about A$5m pre-tax on about A$30m of invested capital (equity less net cash), which is high-teens percent. This is analyst-derived, not company-reported.

Cash conversion cycle: Not publicly disclosed.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Income Statement and Margin Analysis (%)

MetricFY22FY23FY24FY25FY26

Revenue (AUD Mn)

72.683.691.7111.5114.5

Revenue growth reported (%)

16159.621.62.7

Gross profit (AUD Mn)

———66.770.0

Group gross margin (%)

———59.961.1

MAS device gross margin (%)

7072—70.371.5

Underlying EBITDA (AUD Mn)

1.32.10.69.210.9

EBITDA margin (%)

1.82.50.78.29.6

Loss before tax (AUD Mn)

———-0.8-0.5

Income tax expense (AUD Mn)

———-2.7-2.2

Net profit after tax (AUD Mn)

—-8.0-12.2-3.5-2.7

Net margin (%)

—-9.6-13.3-3.1-2.3

EPS basic (A$ cents)

—-7.4-7.6-1.6-1.2

Dividends per share (A$ cents)

00000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement

Metric1H FY241H FY251H FY262H FY26

Revenue (AUD Mn)

45.153.760.753.8

Underlying EBITDA (AUD Mn)

-1.15.87.83.1

NPAT (AUD Mn)

—-0.10.8-3.4

Balance Sheet

MetricFY22FY23FY24FY25FY26

Total assets (AUD Mn)

———81.075.0

Cash and equivalents (AUD Mn)

15.6—16.217.317.2

Trade and other receivables (AUD Mn)

———18.514.5

Inventories (AUD Mn)

———7.47.4

Property, plant and equipment (AUD Mn)

———7.07.6

Intangible assets incl. goodwill (AUD Mn)

———21.522.4

Right-of-use assets (AUD Mn)

———6.94.7

Trade and other payables (AUD Mn)

———19.516.4

Borrowings excl. leases (AUD Mn)

———0.80.4

Lease liabilities (AUD Mn)

———7.25.0

Total liabilities (AUD Mn)

———34.627.6

Net cash excl. leases (AUD Mn)

———16.516.8

Shareholders' equity (AUD Mn)

—24.545.946.447.4

Long-term debt incl. leases per Morningstar (AUD Mn)

—20.94.15.2—

Cash Flow

MetricFY22FY23FY24FY25FY26

Underlying EBITDA (AUD Mn)

1.32.10.69.210.9

Operating cash flow before leases (AUD Mn)

———7.88.3

Lease payments (AUD Mn)

———-3.0-3.1

Operating cash flow after leases (AUD Mn)

———4.85.2

Capex – PP&E (AUD Mn)

———-2.4-3.3

Capex – intangibles (AUD Mn)

———-1.6-2.5

Total capex (AUD Mn)

———-4.0-5.7

Free cash flow after leases (AUD Mn)

———0.8-0.6

Dividends paid (AUD Mn)

00000

Share buybacks (AUD Mn)

00000

Equity raised gross (AUD Mn)

015.522.600

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY23FY24FY25FY26

ROE (%)

-32.1-20.0-7.4-5.6

ROA (%)

——-4.3-3.5

Return on capital per Morningstar (%)

-13-14-6—

Debt (excl. leases) / equity (x)

——0.020.01

Net debt / EBITDA (x)

——-1.8-1.5

Asset turnover (x)

——1.381.48

Interest coverage, EBITDA / interest (x)

——92—

Region revenue (AUD Mn)

Region revenue (AUD Mn)FY23FY24FY25FY26

Europe (FY23 ex-HIC)

47.3—6161.9

North America

30.2—4346

APAC (FY23 derived residual incl. HIC)

6.1—77

Group

83.691.7111.5114.5

Region growth reported (%)

Region growth reported (%)FY23FY25FY26

Europe

12—1

North America

22—7

APAC

——-3

Group

1521.62.7

Share Price & Returns

Reference pointPrice (AUD)Source

30 June 2021

2.21

Market Index

30 June 2022

1.19

Market Index

30 June 2023

0.955

Market Index

2 May 2024 (all-time-low zone)

0.20

InvestSMART

16 September 2025 (block trade)

0.70

ASX

13 January 2026

0.725

InvestSMART

27 February 2026 (1H result)

0.66

InvestSMART

27 July 2026 (pre-update)

0.47

InvestSMART

31 August 2026

0.335

FNArena

1 October 2026

0.30

Investing.com

Share price at 30 June (AUD)

FY22

FY23

SOM closing price (AUD)

1.190.955

Total return (approximate, to about A$0.30, 1 October 2026)

Total return (approximate, to about A$0.30, 1 October 2026)Return

1-year (from about A$0.70, October 2025)

about –57%

3-year (from about A$0.45, October 2023)

about –33%

5-year (from about A$2.30, October 2021)

about –87%

Valuation Multiples

MultipleSomnoMedBasis

Market cap

about A$66m

Investing.com

Enterprise value (excl. leases)

about A$49m

Market cap less net cash of A$16.8m

EV / FY26 underlying EBITDA

about 4.5x

A$49m / A$10.9m

EV / FY26 sales

about 0.43x

A$49m / A$114.5m

P / book

about 1.4x

A$66m / A$47.4m

P / E

n/m (loss)

—

Peer context

ResMed and Inspire trade at materially higher EV/sales and EV/EBITDA (not quantified here; verify live)

—

Analyst Ratings & Targets

BrokerRatingTarget (AUD)Date

Morgans

Speculative Buy

0.76

31 August 2026

Canaccord Genuity

Buy

1.00—

Consensus (Investing.com)

—

0.837 average (range 0.76–0.99)

October 2026

Stockopedia consensus

—0.99—

Analyst Conclusions

Management guidance

FY27: High-single-digit revenue growth, which implies about A$122–126m, with EBITDA margin consistent with FY26 (about 9.6%). That implies EBITDA of about A$11.7–12.1m on analyst arithmetic. The formal range is to be issued at the 23 November 2026 AGM, alongside a detailed strategic roadmap.

FY27–FY30: Return to double-digit revenue growth; progressive EBITDA margin expansion; organic focus with possible small acquisitions.

Consensus

Broker targets of A$0.76–1.00 imply that the market price embeds substantial scepticism, at a 60–70% discount to targets.

Bull case

  1. The cash-generating core is mispriced. At about 4.5x EV/EBITDA and about 0.4x EV/sales, with A$16.8m net cash and 71.5% device gross margins, the market is valuing SomnoMed as if FY26's 2H decline were permanent. Delivering even the FY27 target (about A$12m EBITDA) re-rates the stock toward broker targets.

  2. North America is a compounding growth engine. About 40% of revenue is growing about 11% in constant currency, CMS-code-targeted products are coming, and the GLP-1-expanded diagnosis funnel could support double-digit group growth once Europe stabilises.

  3. Optionality from Rest Assure and Virtus. The only FDA-cleared compliance-monitoring OAT, launching in FY27, plus a device for the roughly 50% of OSA patients with bruxism, give SomnoMed differentiated, premium-priced products against low-cost labs.

Bear case

  1. Growth has structurally decelerated. Group growth fell from 21.6% (FY25) to 2.7% (FY26), the 2H was negative, and Europe (54% of revenue) faces reimbursement and referral headwinds that management cannot control.

  2. Execution and credibility risk. There have been two guidance misses or cuts in three years, a CEO structure change at the moment of a miss, a Chair departure within four months, and a newly promoted COO and CMO. Investor trust must be rebuilt before any re-rating.

  3. Therapeutic substitution and price pressure. GLP-1s and future OSA drugs may shrink the severe-OSA pool, neurostimulation captures CPAP failures, and lower-cost OAT erodes pricing. Meanwhile, share-based payments (A$3.6m) and tax keep statutory earnings negative.

Catalysts and monitorables (next 12 months)

TimingCatalyst
23 November 2026AGM: formal FY27 guidance range, strategic roadmap, Andrew Price takes the Chair, vote on Remuneration Report and option plans
1H FY27 (December 2026 half)Seasonally strongest period; evidence of European stabilisation and North America momentum
February 20271H FY27 results (TDM escrow already expired; watch for overhang)
2H FY27Virtus broad global adoption (key guidance assumption)
FY27Rest Assure commercial launch; progress of the US clinical study toward a treated-AHI 510(k)
OngoingAUD/USD and AUD/EUR rates; European reimbursement decisions; any bolt-on M&A; substantial-holder movements (TDM 25%; June 2026 entrant)

Analyst verdict

SomnoMed enters FY27 as a company whose operational repair is largely complete but whose growth story is unproven again. The FY24–FY26 turnaround was real and measurable:

  • Revenue rose from A$91.7m to A$114.5m.

  • Underlying EBITDA rose from A$0.6m to A$10.9m.

  • Manufacturing capacity grew about 40% and turnaround times halved.

  • Debt was eliminated, leaving A$16.8m of net cash.

Few small-cap medtech companies have rebuilt so thoroughly after a near-crisis that required raising equity at A$0.21 in 2024.

Yet the market has re-rated the shares down by more than half in 2026, for defensible reasons. The FY26 revenue miss came from SomnoMed's largest and most mature region, Europe, and stemmed from reimbursement and referral changes the company does not control. The guidance miss coincided with the departure of one co-CEO, the Chair is now leaving, and the FY27 target of high-single-digit growth is modest against a business that grew 22% a year earlier. Statutory losses persist, driven partly by share-based payments equal to a third of EBITDA, which governance-focused investors will scrutinise at the November AGM.

At about A$0.30, investors pay about A$49m of enterprise value for a global category leader generating about A$11m of underlying EBITDA. That price embeds little value for North American growth, Virtus or Rest Assure. The asymmetry is attractive, but the thesis now depends on near-term proof rather than vision:

  1. Credible FY27 guidance at the AGM.

  2. A stabilising European 1H FY27.

  3. Visible Virtus uptake.

  4. A dated, de-risked Rest Assure commercial launch.

Verdict: Speculative, value-supported recovery situation. The rating should be revisited after the November 2026 AGM guidance and the February 2027 half-year result, which together will show whether FY26's 2H was a pause or a new trend.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenureBackgroundEducation / age

Karen Borg

Chief Executive Officer and Executive Director

Director since 26 November 2020; Co-CEO from c. 2023; sole CEO since 27 July 2026

Former CEO of Catholic Healthcare Ltd; CEO of Healthdirect; inaugural CEO of Jobs for NSW; senior roles in FTSE 100–250 medical device, technology and consumer companies; early career at Goodman Fielder, Nestlé and Revlon; board of KOPWA Aged Care Services; former Interim Chair of the Australian Vaccine Research Alliance

Not publicly disclosed in retrieved materials

Ye-Fei Guo

Chief Financial Officer

—

Presented FY26 results

—

Greg Knight

Chief Operating Officer

Promoted 27 July 2026 from Chief Transformation Officer (role created 1H FY26)

Oversees global manufacturing and operations

—

Nathan Minnich

Chief Marketing Officer

Role created 1H FY26

Leads global marketing

—

Amrita Blickstead (former)

Co-CEO and Executive Director

Board c. 2020; executive about 3.5 years; departed 27 July 2026

Led the turnaround with Borg. Held 2,392,364 shares, 1,885,000 options and 600,000 zero-exercise-price options at exit.

—

Neil Verdal-Austin (former)

Managing Director/CEO

Led the company through FY22–FY23

——

“—” = not publicly disclosed.

Board of Directors

DirectorRoleAppointedIndependenceNotes

Guy (Gaetano) Russo

Non-Executive Chair

Chair since August 2020

Independent

Retiring at the 23 November 2026 AGM; bought 665,000 shares at A$0.443 in December 2024

Andrew Price

Non-Executive Director; Chair-elect

17 January 2025

Independent (presumed)

Standing for re-election in November 2026; to become Chair

Benjamin Gisz

Non-Executive Director

8 October 2024

Not independent. Nominee of TDM Growth Partners, the largest shareholder

Director and investment team member at TDM; standing for re-election in November 2026

Karen Borg

CEO and Executive Director

26 November 2020

Executive

—

Hamish Corlett (former)

NED (TDM nominee)

1 May 2018 – 8 October 2024

—

Replaced by Gisz

Hilton Brett (former)

Director

Resigned 12 October 2023

——

Governance Timeline

DatePersonInstrumentQuantityStated value

28 June 2024

Karen Borg

Options issued

750,000

A$189,375

1 July 2024

Karen Borg

Options issued

575,000

A$155,250

1 July 2025

Karen Borg

Securities issued

600,000

A$384,000

6 August 2025

Karen Borg

Options exercised

750,000

A$588,750

4 December 2025

Karen Borg

Options issued (post-AGM)

1,700,000

A$1,360,000

4 December 2025

Benjamin Gisz

Options issued

200,000

A$160,000

23 July 2026

Karen Borg

Options exercised / shares acquired

575,000

A$270,250

Major Shareholders

HolderShares% (approx.)Date / source

TDM Growth Partners / TDM Asset Management and associates

54,504,649 (plus 300,000 options)

25.0

After block trade, 16 September 2025 (FilingReader / ASX)

Unnamed new substantial holder

—

≥5

—

Karen Borg (CEO)

Not fully verified; includes 476,191 rights-issue shares (2024) plus option exercises

<2

Director notices

Guy Russo (Chair)

≥665,000

<1

December 2024 notice

Other top-10 holders

——

Annual Report 2026 top-20 list

“—” = not publicly disclosed.

Competitive Landscape

Key Competitors

CompetitorSegment overlapScale (latest, approx.)Positioning vs SomnoMed

ResMed (NYSE: RMD / ASX: RMD) – including the Narval CC oral appliance

CPAP (substitute) and OAT (direct)

—

Dominant OSA company; its CPAP is first-line, while OAT is a niche for ResMed

Philips Respironics

CPAP (substitute)

Segment not separately comparable

Weakened after the 2021 recall and US consent decree; indirectly benefits OAT

Fisher & Paykel Healthcare (NZX/ASX: FPH)

CPAP masks (substitute)

Revenue about NZ$2.0bn (FY25) – from memory

Mask leader; not an OAT maker

Inspire Medical Systems (NYSE: INSP)

Hypoglossal nerve stimulation (substitute for CPAP-intolerant patients)

Revenue about US$800m (CY2024) – from memory

High-cost, surgical; competes for the same "CPAP failure" patient

Eli Lilly – Zepbound (tirzepatide)

Pharmacotherapy (FDA-approved for OSA in obesity, December 2024)

n/m

Both threat and funnel: drives diagnosis, may reduce severity, and SomnoMed engages a GLP-1 maker

Apnimed (AD109, private)

Investigational oral OSA drug

Pre-commercial

Potential long-term substitute

Glidewell Laboratories (private, US)

OAT (EMA, Silent Nite, others)

—

Large US dental lab; price competitor

ProSomnus (US; formerly Nasdaq: OSA)

Precision OAT (US)

Revenue about US$27–30m (2023) – from memory; restructured and taken private in 2024

Direct US competitor in digitally manufactured OAT

Panthera Dental (private, Canada)

CAD/CAM OAT (D-SAD, others)

—

Direct competitor in North America and Europe

Vivos Therapeutics (Nasdaq: VVOS)

Oral appliances / airway (US)

Revenue about US$15m (2024) – from memory

Niche, differentiated "remodelling" claims

Airway Management (private, US; TAP/myTAP)

OAT

—

US competitor

OrthoApnea (Spain), Somnowell, Erkodent, local dental labs

OAT (Europe)

—

Lower-cost European competitors

“—” = not publicly disclosed.

Peer Comparison FY2026

MetricSomnoMed (FY26)ResMed (FY25)Inspire (CY24)ProSomnus (CY23)

Revenue (local currency, millions)

A$114.5

about US$5,100

about US$800

about US$28

Revenue growth (%)

3

about 10

about 28

—

Gross margin (%)

61.1

about 59

about 85

—

EBITDA / operating margin (%)

9.6 (underlying EBITDA)

about 30+ (operating)

low single-digit (operating)

negative

R&D intensity (%)

about 2 (capitalised only; total not disclosed)

about 6–7

about 10+

—

Company Snapshot

$73.9M

Revenue

400

Employees

2004

Founded

Crows Nest, Australia

Headquarters

SWOT Analysis

Strengths

  • Category leadership and scale. It is the first OAT company to treat more than one million patients (FY25 results, August 2025), with leading positions across three regions.
  • High unit economics. MAS device gross margin was 71.5% in FY26, up from 70.3% (FY26 presentation).
  • Debt-free balance sheet. Net cash was A$16.8m at 30 June 2026, with residual debt of only A$0.4m in European government-backed loans (FY26 presentation).
  • Restored profitability. Underlying EBITDA rose from A$0.6m (FY24) to A$10.9m (FY26), with margin expanding from 0.7% to 9.6%.
  • Regulatory first-mover technology. Rest Assure FDA 510(k) K233497, cleared 3 October 2024, is the first OAT cleared for in-built compliance monitoring.
  • Rebuilt manufacturing capability. Capacity is up more than 40% and production times are down more than 50% over FY25–FY26, the backlog has been eliminated, and North America is growing about 11% in constant currency.

Weaknesses

  • Persistent statutory losses. NPAT was –A$2.65m in FY26 and –A$3.5m in FY25, burdened by A$3.6m of share-based payments and a high effective tax rate (Appendix 4E FY26).
  • Guidance credibility. FY24 guidance was cut in April 2024, and FY26 revenue of A$114.5m missed the A$119–126m guide by A$4.5m at the bottom of the range (27 July 2026).
  • Concentration in Europe. Europe is 54% of revenue and its constant-currency growth fell to –1% in FY26.
  • Weak free cash flow. FCF after leases was –A$0.6m in FY26 as capex rose to A$5.7m (FY26 presentation).
  • Small, illiquid equity. Market cap is about A$66m (October 2026), daily volumes are thin, and TDM holds 25%.
  • Leadership churn. It moved from co-CEO to sole CEO in July 2026, the Chair departs in November 2026, and the COO and CMO are new in role.

Opportunities

  • Rest Assure commercialisation (FY27). Objective adherence data could unlock physician confidence and premium pricing. Canaccord retains a Buy rating with a A$1.00 target on industry feedback.
  • Virtus addressable cohort. About 50% of OSA patients have bruxism (Li et al. 2023); the global controlled release began in July 2026.
  • GLP-1-driven diagnosis funnel. The company reports engagement with a GLP-1 manufacturer, and pharma is "driving patient growth" (FY26 presentation).
  • CPAP-failure conversion. Up to 50% of CPAP users discontinue, creating a large referral pool.
  • US reimbursement-code optimisation. Product innovation targets the most accessible CMS codes.
  • Small bolt-on M&A. This was explicitly added to the FY27–FY30 strategy, funded from net cash.

Threats

  • European reimbursement and referral reform. This produced a roughly 600bp FY26 growth drag including FX (27 July 2026 release).
  • Pharmacotherapy substitution. Tirzepatide's OSA approval and drugs in development such as AD109 could reduce OSA severity and the need for devices over time.
  • Neurostimulation. Inspire and others target the same CPAP-intolerant patients with surgical solutions.
  • Low-cost OAT competitors. Management flags growth in lower-cost products and clinical differentiation challenges.
  • FX. About 95% of revenue is non-AUD, and AUD appreciation cut FY26 2H reported growth by about 6 points.
  • Regulatory dependency of Rest Assure. The efficacy (treated-AHI) claim was not cleared in 2024 and requires a US clinical study and a further 510(k), so delays are possible.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
28 February 2025 (context)1H FY25: revenue A$53.7m (+19%), EBITDA A$5.8m; FY25 guidance raised to about A$105mTurnaround visible
1 July 2025600,000 securities issued to CEO BorgIncentive alignment
28 July 2025Q4 FY25 update: Q4 revenue +25.1% year on year; FY25 to exceed guidancePositive momentum
6 August 2025Borg exercises 750,000 optionsInsider participation
28 August 2025FY25 results: record revenue A$111.5m (+21.6%), EBITDA A$9.2m, net cash A$16.5m, one million patients; FY26 guidance A$119–126mPeak-confidence moment
28 August 2025Annual Report 2025 releasedPrimary filing
16 September 2025Block trade of 16.07m shares at A$0.70; TDM falls from 31.3% to 25.0%; TDM escrow to February 2026Larger free float; overhang created post-escrow
20 October 2025Investor presentation (conference)IR activity
29 October 2025Q1 FY26 revenue +13.5%On track for guidance
26 November 2025FY25 slides (per aggregator)IR
27 November 2025AGM: Rest Assure US clinical study and FDA protocol progress; guidance reaffirmedTechnology milestone
4 December 2025Options issued to Borg (1.7m) and Gisz (200k) following AGM approvalRemuneration
13 January 2026Application for quotation of securitiesOption or share issuance
13 February 20261H FY26 results webinar notice—
27 February 20261H FY26: revenue A$60.7m (+13%), EBITDA A$7.8m (+35%), NPAT A$0.79m, cash A$18.0m; CMO and CTO hires; FY26 guidance reaffirmed; Rest Assure commercialisation expected FY27Share price fell sharply on the day (InvestSMART shows the release at A$0.66)
9 March 2026Cessation and quotation of securitiesOption lapses / exercises
18–20 March 2026Quotation and unquoted securities noticesEquity plan activity
18 June 2026New ≥5% holder
22–24 July 2026Quotation of securities; Borg exercises and buys 575,000 shares (23 July)Insider buying before the update
27 July 2026Preliminary FY26: revenue A$114–115m (below guidance), EBITDA mid-range; Europe reimbursement and referral changes plus AUD strength (about 600bp impact); Co-CEO Blickstead exits; Borg sole CEO; Greg Knight COO; Virtus launch; FY27 high-single-digit growth targetGuidance miss; shares fell about 22% to about A$0.37
27 July 2026Final Director's Interest Notice: BlicksteadGovernance
14 and 19 August 2026—
28 August 2026FY26 Appendix 4E, Annual Report and presentation: revenue A$114.5m, EBITDA A$10.9m, NPAT –A$2.65m, net cash A$16.8mConfirms preliminary numbers
28 August 2026Four Change of Director's Interest noticesEquity plan adjustments
31 August 2026Morgans retains Speculative Buy, target A$0.76 (+1c); describes the stock as too cheap at below 8x EV/EBITDABroker support
4 September 2026Notification of cessation of securitiesOption lapses
1 October 2026Share price about A$0.30; market cap about A$66mMulti-year low territory
16 October 2026Chair Guy Russo to retire; Andrew Price Chair-elect; AGM notice for 23 November 2026 (re-election of Gisz and Price; plan refreshes; 400k options to Michael Gordon)Governance transition; FY27 guidance and strategy roadmap due at AGM

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

1 chart
Revenue by Region: Europe (FY23 ex-HIC) rose from AUD 47.3 Mn in FY2023 to AUD 61.9 Mn in FY2026.
SomnoMed Limited — Revenue by Region
Series (AUD Mn)FY2023FY2024FY2025FY2026
Europe (FY23 ex-HIC)47.3—6161.9
North America30.2—4346
APAC (FY23 residual incl. HIC)6.1—77
Group83.691.7111.5114.5

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.